TGF-beta signal transduction in chronic kidney disease.

Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol (2011) 3.68

Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int (2011) 2.28

Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. J Am Soc Nephrol (2013) 2.13

Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria. Kidney Int (2011) 1.94

Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol (2010) 1.93

Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population. Am J Kidney Dis (2011) 1.88

Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. Kidney Int (2012) 1.66

Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol (2011) 1.62

Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling. J Biol Chem (2010) 1.41

Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol (2012) 1.19

Interdependence of HIF-1α and TGF-β/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol (2011) 1.07

Genetic deficiency of Smad3 protects against murine ischemic acute kidney injury. Am J Physiol Renal Physiol (2011) 1.01

Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med (2010) 0.98

Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br J Pharmacol (2011) 0.97

Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. Am J Physiol Renal Physiol (2013) 0.93

Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29. Am J Pathol (2013) 0.92

Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol (2014) 0.91

Inhibition of proinflammatory RANTES expression by TGF-beta1 is mediated by glycogen synthase kinase-3beta-dependent beta-catenin signaling. J Biol Chem (2010) 0.88

Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression. J Am Soc Nephrol (2015) 0.84

Distinct mesenchymal alterations in N-cadherin and E-cadherin positive primary renal epithelial cells. PLoS One (2012) 0.83

P311 promotes renal fibrosis via TGFβ1/Smad signaling. Sci Rep (2015) 0.82

Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model. PLoS One (2015) 0.82

Inhibition of the K+ channel K(Ca)3.1 reduces TGF-β1-induced premature senescence, myofibroblast phenotype transition and proliferation of mesangial cells. PLoS One (2014) 0.82

A cationic-independent mannose 6-phosphate receptor inhibitor (PXS64) ameliorates kidney fibrosis by inhibiting activation of transforming growth factor-β1. PLoS One (2015) 0.81

Cross regulation between hypoxia-inducible transcription factor-1α (HIF-1α) and transforming growth factor (TGF)-ß1 mediates nickel oxide nanoparticles (NiONPs)-induced pulmonary fibrosis. Am J Transl Res (2015) 0.81

Elevated serum 1,25(OH)2-vitamin D3 level attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction in kl/kl mice. Sci Rep (2014) 0.80

Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol (2012) 0.80

Interleukin-13 inhibits cytokines synthesis by blocking nuclear factor-κB and c-Jun N-terminal kinase in human mesangial cells. J Biomed Res (2010) 0.79

Inhibition of Advanced Glycation End Products (AGEs) Accumulation by Pyridoxamine Modulates Glomerular and Mesangial Cell Estrogen Receptor α Expression in Aged Female Mice. PLoS One (2016) 0.77

A maladaptive role for EP4 receptors in mouse mesangial cells. PLoS One (2014) 0.77

Hypoxia-inducible factor-1α promotes glomerulosclerosis and regulates COL1A2 expression through interactions with Smad3. Kidney Int (2016) 0.77

Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration. Int J Biol Sci (2015) 0.75

Notch signaling mediated by TGF-β/Smad pathway in concanavalin A-induced liver fibrosis in rats. World J Gastroenterol (2017) 0.75

Interpreting gene-expression profiles in transplantation: a critical appraisal. Front Genet (2011) 0.75

Transforming growth factor-β receptor 2 gene polymorphisms are associated with end-stage renal disease. Kidney Res Clin Pract (2015) 0.75

Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis. Oncotarget (2016) 0.75

Cell-Based Therapies for Tissue Fibrosis. Front Pharmacol (2017) 0.75

Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 16.46

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell (1999) 11.59

The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell (2001) 10.02

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91

Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol (2003) 7.74

Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science (1999) 7.51

New insights into TGF-beta-Smad signalling. Trends Biochem Sci (2004) 6.13

Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J (2002) 5.44

PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell (2006) 5.28

The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int (2007) 5.15

MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92

Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J (2004) 4.77

SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell (1998) 4.51

Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol (2001) 4.39

TGF-beta signaling in renal disease. J Am Soc Nephrol (2002) 4.21

Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature (1992) 3.96

Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell (2003) 3.80

Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol (1997) 3.67

A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell (2003) 3.57

Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest (2001) 3.40

Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J (1999) 3.28

A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol (2007) 3.23

DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol (1999) 3.17

Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J (2004) 3.17

Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16

A Smad transcriptional corepressor. Cell (1999) 3.07

hnRNP K: one protein multiple processes. Bioessays (2004) 2.96

Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell (2007) 2.92

Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89

TGF-beta signaling: a tale of two responses. J Cell Biochem (2007) 2.83

Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J (2006) 2.80

Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol (1989) 2.77

Molecular basis of renal fibrosis. Pediatr Nephrol (2000) 2.71

Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res (2006) 2.59

Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol (2004) 2.53

The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev (1999) 2.52

Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol (2008) 2.35

TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol (2002) 2.34

c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem (1999) 2.32

Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene (2005) 2.24

Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) (2005) 2.23

Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int (2004) 2.21

Expression of connective tissue growth factor in human renal fibrosis. Kidney Int (1998) 2.19

Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J (2003) 2.15

Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens (2005) 2.04

GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor. J Cell Biol (2004) 1.98

Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J Biol Chem (2003) 1.97

Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest (1993) 1.97

Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol (2002) 1.96

Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling. Genes Dev (2008) 1.93

Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene (2006) 1.89

Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol (2000) 1.87

Transforming growth factor beta and cell cycle regulation. Cancer Res (1995) 1.84

Endoglin in angiogenesis and vascular diseases. Angiogenesis (2008) 1.83

Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol (2007) 1.79

The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1. J Biol Chem (2003) 1.79

Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol (2006) 1.79

Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem (2005) 1.77

Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest (1997) 1.75

Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann N Y Acad Sci (2003) 1.74

The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J (2006) 1.72

The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J (2001) 1.72

Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int (1994) 1.70

Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J Biol Chem (2000) 1.70

Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol (2005) 1.70

Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol (2001) 1.69

Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol (2005) 1.67

p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int (2005) 1.67

Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev (2003) 1.66

Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science (2000) 1.66

Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. EMBO J (2002) 1.66

Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell (2005) 1.65

Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol (2004) 1.64

Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J Biol Chem (2006) 1.63

GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene (2000) 1.62

Protein kinase CK2 mediates TGF-beta1-stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int (2001) 1.61

Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes (1997) 1.59

Internalization-dependent and -independent requirements for transforming growth factor beta receptor signaling via the Smad pathway. Mol Cell Biol (2002) 1.58

Upregulation of ID protein by growth and differentiation factor 5 (GDF5) through a smad-dependent and MAPK-independent pathway in HUVSMC. J Mol Cell Cardiol (2006) 1.58

Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun (2005) 1.58

Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol (2004) 1.57

ZFHX1B mutations in patients with Mowat-Wilson syndrome. Hum Mutat (2007) 1.55

The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood (2001) 1.53

Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem (2002) 1.53

Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2(I)-collagen (COL1A2) transcription. J Biol Chem (2000) 1.52

TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene (2004) 1.52

Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol (2000) 1.51

Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol (2006) 1.49

Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int (2000) 1.49

Mesenchymal transition in kidney collecting duct epithelial cells. Am J Physiol Renal Physiol (2008) 1.49

TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int (1999) 1.49

A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol (2004) 1.48

Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol (2004) 1.46

BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol (2003) 1.46

The activated mesangial cell: a glomerular "myofibroblast"? J Am Soc Nephrol (1992) 1.44

Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int (2004) 1.44

Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol (2002) 1.41

Regulation of Smad activities. Biochim Biophys Acta (2006) 1.41

The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. J Biol Chem (2004) 1.39

A complementary transposon tool kit for Drosophila melanogaster using P and piggyBac. Nat Genet (2004) 8.55

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23

Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med (2011) 2.20

TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol (2003) 2.13

Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int (2005) 1.71

Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. Kidney Int (2012) 1.66

Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med (2010) 1.51

Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens (2002) 1.49

It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol (2002) 1.39

Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in critically ill children (AWARE): study protocol for a prospective observational study. BMC Nephrol (2015) 1.21

Interdependence of HIF-1α and TGF-β/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol (2011) 1.07

Rac1 promotes TGF-beta-stimulated mesangial cell type I collagen expression through a PI3K/Akt-dependent mechanism. Am J Physiol Renal Physiol (2009) 1.06

Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation. J Biol Chem (2007) 1.00

Role of SARA (SMAD anchor for receptor activation) in maintenance of epithelial cell phenotype. J Biol Chem (2009) 0.99

Cytoskeletal rearrangement and signal transduction in TGF-beta1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol (2003) 0.93

Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. Am J Physiol Renal Physiol (2013) 0.93

Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation (2004) 0.93

Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. Bioorg Med Chem (2006) 0.92

TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression. Am J Physiol Renal Physiol (2013) 0.91

Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens (2002) 0.90

Overland and near-surface transport of Cryptosporidium parvum from vegetated and nonvegetated surfaces. J Environ Qual (2004) 0.88

A conceptual framework for the molecular pathogenesis of progressive kidney disease. Pediatr Nephrol (2010) 0.87

Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. Clin Ther (2002) 0.86

Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens (2005) 0.84

RACK1 binds to Smad3 to modulate transforming growth factor-beta1-stimulated alpha2(I) collagen transcription in renal tubular epithelial cells. J Biol Chem (2006) 0.84

Hemodynamic and hormonal patterns of untreated essential hypertension in men and women. Ther Adv Cardiovasc Dis (2013) 0.82

Noninvasive hemodynamic profiles in hypertensive subjects. Am J Hypertens (2005) 0.82

Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther (2003) 0.81

Role of olmesartan in combination therapy in blood pressure control and vascular function. Vasc Health Risk Manag (2010) 0.79

Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. Kidney Int Suppl (2002) 0.78

Intrahepatic porto-hepatic venous shunts in Rendu-Osler-Weber disease: imaging demonstration. Eur Radiol (2003) 0.78

Pediatric sepsis: preparing for the future against a global scourge. Curr Infect Dis Rep (2012) 0.76

The role of noninvasive hemodynamic monitoring in the evaluation and treatment of hypertension. Ther Adv Cardiovasc Dis (2007) 0.76

Cost-effectiveness of impedance cardiography testing in uncontrolled hypertension. Am Heart Hosp J (2006) 0.76

Acute Kidney Injury in Pediatric Severe Sepsis: An Independent Risk Factor for Death and New Disability. Crit Care Med (2016) 0.75

Amlodipine and losartan: reaction to comparison. J Clin Hypertens (Greenwich) (2003) 0.75

Optimal Role of the Nephrologist in the Intensive Care Unit. Blood Purif (2016) 0.75

BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN. Biochem Pharmacol (1974) 0.75

Catalytic activity of thiacalix[4]arenetetrasulfonate metal complexes on modified anion-exchangers for ascorbic acid oxidation. Chem Pharm Bull (Tokyo) (2013) 0.75

Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy. Hypertens Res (2009) 0.75

Association between antihypertensive agent use and hospital admissions in a managed care population. Am J Med Sci (2004) 0.75

Schwabe Symposia 2004-2006. Forward. Prev Vet Med (2008) 0.75

Schwabe symposium 2007 on field disease investigation and population health-a symposium honoring the legacy of Dr. Clive C. Gay, Professor Emeritus from Washington State University. Prev Vet Med (2008) 0.75